1 min read

Let’s Talk Medtech & CLEERLY

Picture of Cleerly Cleerly : April 6, 2022

It’s American Heart Month, and Cleerly, a startup that uses artificial intelligence to change the way we diagnose cardiovascular disease is keeping busy.

Dr. James Min, founder and CEO of Cleerly, joins us on this episode of Let’s Talk Medtech for a riveting discussion about cardiovascular disease during American Heart Month.

Omar Ford | Feb 11, 2022

Dr. James, “Jim” Min, founder and CEO of Cleerly, joins us on this episode of Let's Talk Medtech for a discussion about American Heart Month and the company’s goals over the next few months.

Cleerly’s technology was born out of research from the Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine and uses non-invasive coronary (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions.

This technology is based on millions of annotated lab images used to build more than two dozen algorithms capable of quantifying and characterizing the presence, extent, severity, and type of coronary artery disease and other cardiovascular disorders. Read full article HERE.

AI Leading the Way to More Precise Diagnostics and Disease Risk Prediction

Cleerly: February 15, 2024

Inside Precision Medicine features our Chief Scientific Officer, Dr. Udo Hoffmann, on how AI has changed CT imaging and the TRANSFORM trial that may...